www.flt3mutationaml.com Open in urlscan Pro
40.121.8.241  Public Scan

Form analysis
0 forms found in the DOM

Text Content

THANK YOU FOR VISITING

BY CLICKING "CONTINUE," YOU WILL LEAVE THIS SITE.

CONTINUE CANCEL

This website is funded and developed by Astellas Pharma US, Inc.

 * For Healthcare Professionals
 * Medical Inquiry


MENU
 * Home
 * Impact of flt3 mutations
 * How to identify flt3 mutations


CONFIRM FLT3 MUTATION STATUS AT RELAPSE OR PROGRESSION IN PATIENTS WITH AML TO
INFORM TREATMENT DECISIONS1

Your browser does not support HTML5 video.



IN PATIENTS WITH AML, A FLT3-ITD  MUTATION DRIVES PROGRESSION AND MAY LEAD TO
LOWER SURVIVAL2-4

See the impact of a FLT3 mutation



DISCOVER FLT3 MUTATION STATUS BY TESTING AML PATIENTS AT RELAPSE OR PROGRESSION1

Learn more about testing for mutations

Learn more about FLT3 mutations and their impact in AML

Download the brochure
Download the brochure
AML=acute myeloid leukemia; FLT3=FMS-like tyrosine kinase 3; ITD=internal tandem
duplication.

References: 1. Referenced with permission from the NCCN Clinical Practice
Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2022. ©
National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed
06-30-2022. To view the most recent and complete version of the guideline, go
online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding
their content, use or application and disclaims any responsibility for their
application or use in any way. 2. Patel JP, Gönen M, Figueroa ME, et al.
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
N Engl J Med 2012;366(12):1079-89. 3. Chevallier P, Labopin M, Turlure P, et al.
A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute
myelogeneous leukaemia patients: a GOELAMS study. Leukemia 2011;25(6):939-44. 4.
Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a
therapeutic target in human acute myeloid leukaemia. Nature
2012;485(7397):260-3. 5. Gale RE, Green C, Allen C, et al. The impact of FLT3
internal tandem duplication mutant level, number, size, and interaction with
NPM1 mutations in a large cohort of young adult patients with acute myeloid
leukemia. Blood 2008;111(5):2776-84. 6. McCormick SR, McCormick MJ, Grutkoski
PS, et al. FLT3 mutations at diagnosis and relapse in acute myeloid leukemia:
cytogenetic and pathologic correlations, including cuplike blast morphology.
Arch Pathol Lab Med 2010;134(8):1143-51. 7. Leisch M, Jansko B, Zaborsky N,
Greil R, Pleyer L. Next generation sequencing in AML—on the way to becoming a
new standard for treatment initiation and/or modulation? Cancers (Basel) (Epub)
02-21-2019. 8. Morita K, Wang F, Jahn K, et al. Clonal evolution of acute
myeloid leukemia revealed by high-throughput single-cell genomics. Nature Commun
2020;11:5327. Erratum in: Nat Commun 2020;11(1):5996. Erratum in: Nat Commun
2021;12(1):2823. 9. Patnaik MM. The importance of FLT3 mutational analysis in
acute myeloid leukemia. Leuk Lymphoma 2018;59(10):2273-86. 10. Invivoscribe.
LeukoStrat® CDx FLT3 mutation assay.
https://catalog.invivoscribe.com/product/leukostrat-cdx-flt3-mutation-assay-2/.
Accessed 10-21-2021. 11. Nazha A, Cortes J, Faderl S, et al. Activating internal
tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at
complete response and relapse in patients with acute myeloid leukemia.
Haematologica 2012;97(8):1242-5. 12. Warren M, Luthra R, Yin CC, et al. Clinical
impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod
Pathol 2012;25(10):1405-12. 13. Burd A, Levine RL, Ruppert AS, et al. Precision
medicine treatment in acute myeloid leukemia using prospective genomic
profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Nat Med 2020;26(12):1852-8.
 * Terms of use/Legal Disclaimer
 * Privacy Policy
 * Contact Us
 * Site Map

© 2022 Astellas Pharma US, Inc. All rights reserved. 074-0531-PM 12/22
Astellas and the flying star logo are registered trademarks of Astellas Pharma
Inc.